KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to $28.6 million.

  • Bio-Rad Laboratories' Non Operating Income rose 4591.84% to $28.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $90.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $90.3 million for FY2025, which is 0.0% changed from last year.
  • Bio-Rad Laboratories' Non Operating Income amounted to $28.6 million in Q4 2025, which was up 4591.84% from $8.3 million recorded in Q3 2025.
  • In the past 5 years, Bio-Rad Laboratories' Non Operating Income ranged from a high of $50.4 million in Q1 2023 and a low of -$600000.0 during Q3 2021
  • For the 5-year period, Bio-Rad Laboratories' Non Operating Income averaged around $17.9 million, with its median value being $17.7 million (2021).
  • In the last 5 years, Bio-Rad Laboratories' Non Operating Income plummeted by 15911.33% in 2021 and then skyrocketed by 681000.0% in 2022.
  • Bio-Rad Laboratories' Non Operating Income (Quarter) stood at $10.1 million in 2021, then plummeted by 77.16% to $2.3 million in 2022, then surged by 730.43% to $19.1 million in 2023, then grew by 2.62% to $19.6 million in 2024, then skyrocketed by 45.92% to $28.6 million in 2025.
  • Its Non Operating Income was $28.6 million in Q4 2025, compared to $8.3 million in Q3 2025 and $16.2 million in Q2 2025.